Page last updated: 2024-09-03

gefitinib and Precancerous Conditions

gefitinib has been researched along with Precancerous Conditions in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abba, MC; Aldaz, CM; Bissonnette, RP; Brown, PH; Gaddis, S; Hill, J; Hu, Y; Kittrell, FS; Levy, CC; Medina, D1
Bunn, PA; Franklin, W1
Khuri, FR1
Brown, PH; Celestino, J; Hill, J; Hilsenbeck, S; Kim, H; Lu, C; Mohsin, SK; Osborne, CK; Shen, Q; Speers, C; Steinbis, E; Wakeling, A; Xu, X; Zhang, Y1
Aluri, L; Bissonnette, M; Cerda, S; Chumsangsri, A; Cohen, EE; Delgado, J; Dougherty, U; Fichera, A; Hart, J; Jagadeeswaran, S; Joseph, L; Little, N; Mustafi, R; Sehdev, A; Tretiakova, M; Yuan, W1
Bundred, NJ; Chan, KC; Gee, JM; Knox, WF; Morris, J; Nicholson, RI; Potten, CS1

Reviews

2 review(s) available for gefitinib and Precancerous Conditions

ArticleYear
Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
    Seminars in oncology, 2002, Volume: 29, Issue:5 Suppl 14

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Cetuximab; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction

2002
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
    Clinical lung cancer, 2003, Volume: 5 Suppl 1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Quinolones

2003

Other Studies

4 other study(ies) available for gefitinib and Precancerous Conditions

ArticleYear
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.
    Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2

    Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Precancerous Conditions; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Protein, Translationally-Controlled 1; Tumor Suppressor Protein p53

2009
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Journal of the National Cancer Institute, 2003, Dec-17, Volume: 95, Issue:24

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Enzyme Inhibitors; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Transgenic; Microfilament Proteins; Mitogen-Activated Protein Kinases; Muscle Proteins; Phosphorylation; Precancerous Conditions; Quinazolines; Receptors, Estrogen; Signal Transduction

2003
Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Apr-15, Volume: 14, Issue:8

    Topics: Animals; Azoxymethane; CCAAT-Enhancer-Binding Protein-beta; Colonic Neoplasms; Cyclin D; Cyclins; Disease Progression; ErbB Receptors; Gefitinib; Male; Precancerous Conditions; Quinazolines; Rats; Rats, Inbred F344; STAT3 Transcription Factor; Transcription Factor AP-1

2008
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
    Cancer research, 2002, Jan-01, Volume: 62, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cell Division; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Precancerous Conditions; Quinazolines; Xenograft Model Antitumor Assays

2002